Reports Q2 revenue $4.02B, consensus $3.96B. “IQVIA (IQV) delivered strong financial results, with revenue above target and profit towards the high-end of expectations,” said Ari Bousbib, chairman and CEO of Iqvia. “Our TAS segment performed well with high single digits year-over-year revenue growth. In the clinical development business, forward-looking demand indicators improved, with net bookings up 15 percent quarter-over-quarter, and RFP flow growing high single digits sequentially and low teens year-over-year. These results underscore the resilience of our global diversified portfolio and the team’s ability to execute consistently against our strategic and financial objectives.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia price target lowered to $180 from $190 at BofA
- Alnylam price target raised to $360 from $300 at BMO Capital
- IQVIA Holdings Issues $2 Billion in Senior Notes
- Early notable gainers among liquid option names on June 4th
- Mixed Outlook for IQVIA Holdings: Growth Potential Offset by Policy Uncertainties and Margin Shifts